Aptevo Therapeutics Company Leadership
| APVO Stock | USD 0.28 0.07 20.00% |
Aptevo Therapeutics employs about 40 people. The company is managed by 7 executives with a total tenure of roughly 94 years, averaging almost 13.0 years of service per executive, having 5.71 employees per reported executive. Analysis of Aptevo Therapeutics' management performance can provide insight into the firm performance.
Aptevo |
Aptevo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7275) % which means that it has lost $0.7275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5096) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.74. In addition to that, Return On Capital Employed is likely to drop to -1.72. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 2nd of December 2024, Other Current Assets is likely to grow to about 3 M, while Total Assets are likely to drop about 23.6 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 292 K. Also, Net Income Applicable To Common Shares is likely to grow to about 9.7 M
Aptevo Therapeutics Workforce Comparison
Aptevo Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 678. Aptevo Therapeutics holds roughly 40.0 in number of employees claiming about 6% of equities under Health Care industry.
Aptevo Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptevo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptevo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aptevo Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptevo Therapeutics Notable Stakeholders
An Aptevo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aptevo Therapeutics often face trade-offs trying to please all of them. Aptevo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aptevo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Marvin White | CEO President | Profile | |
| Daphne Taylor | Senior CFO | Profile | |
| Daphne CPA | Senior CFO | Profile | |
| Jeffrey CA | Executive COO | Profile | |
| LLM JD | General VP | Profile | |
| Dirk MD | Chief Officer | Profile | |
| Jane Gross | Chief Officer | Profile |
About Aptevo Therapeutics Management Performance
The success or failure of an entity such as Aptevo Therapeutics often depends on how effective the management is. Aptevo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aptevo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aptevo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.70) | (0.74) | |
| Return On Capital Employed | (1.64) | (1.72) | |
| Return On Assets | (0.70) | (0.67) | |
| Return On Equity | (1.42) | (1.50) |
Aptevo Therapeutics Workforce Analysis
Traditionally, organizations such as Aptevo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aptevo Therapeutics within its industry.Aptevo Therapeutics Manpower Efficiency
Return on Aptevo Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 435.3K | |
| Net Loss Per Executive | 2.5M | |
| Working Capital Per Employee | 296.1K | |
| Working Capital Per Executive | 1.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.24) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.